GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apontis Pharma AG (XTER:APPH) » Definitions » Notes Receivable

Apontis Pharma AG (XTER:APPH) Notes Receivable : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Apontis Pharma AG Notes Receivable?

Apontis Pharma AG's Notes Receivable for the quarter that ended in Jun. 2024 was €0.00 Mil.


Apontis Pharma AG Notes Receivable Historical Data

The historical data trend for Apontis Pharma AG's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apontis Pharma AG Notes Receivable Chart

Apontis Pharma AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial - - - - -

Apontis Pharma AG Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Apontis Pharma AG Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Apontis Pharma AG Notes Receivable Related Terms

Thank you for viewing the detailed overview of Apontis Pharma AG's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Apontis Pharma AG Business Description

Traded in Other Exchanges
Address
Alfred-Nobel-Strabe 10, Monheim, BY, DEU, 40789
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
Executives
Bruno Wohlschlegel Board of Directors
Thomas Milz Board of Directors
Thomas Zimmermann Chief Financial Officer
Karlheinz Gast Board of Directors

Apontis Pharma AG Headlines

No Headlines